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Natriuretic peptides (NPs) have been found to be useful markers in differentiating
acute dyspneic patients presenting to the emergency department (ED) and emerg-
ed as potent prognostic markers for patients with congestive heart failure (CHF).
The best-established and widely used clinical application of BNP and NT-
proBNP testing is for the emergent diagnosis of CHF in patients presenting with
acute dyspnea. BNP and NT-proBNP, as the European Society of Cardiology
recommended, are helpful in the diagnosis of HF and providing prognostic
potential; as well at a low-normal concentration in untreated patients makes HF
unlikely as the cause of symptoms.
1 The Food and Drug Administration (FDA)
approved a cutoff value of BNP for the diagnosis of CHF is 100 pg/mL. In NT-
proBNP, the optimal cutoff values for confirmatory (rule in) decision limits for
CHF are 450, 900 and 1,800 pg/mL for ages less than 50 years, between 50 to 75
years, and older than 75 years of age. The exclusionary (rule out) decision limit of
NT-proBNP for cardiogenic acute dyspnea in all ages is less than 300 pg/mL.
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Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients
presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with
congestive heart failure (CHF). The best-established and widely used clinical application of BNP and NT-proBNP
testing is for the emergent diagnosis of CHF in patients presenting with acute dyspnea. Nevertheless, elevated NPs
levels can be found in many circumstances involving left ventricular (LV) dysfunction or hypertrophy; right
ventricular (RV) dysfunction secondary to pulmonary diseases; cardiac inflammatory or infectious diseases;
endocrinology diseases and high output status without decreased LV ejection fraction. Even in the absence of
significant clinical evidence of volume overload or LV dysfunction, markedly elevated NP levels can be found in
patients with multiple comorbidities with a certain degree of prognostic value. Potential clinical applications of NPs
are expanded accompanied by emerging reports regarding screening the presence of secondary cardiac dysfunction;
monitoring the therapeutic responses, risk stratifications and providing prognostic values in many settings.
Clinicians need to have expanded knowledge regarding the interpretation of elevated NPs levels and potential
clinical applications of NPs. Clinicians should recognize that currently the only reasonable application for routine
practice is limited to differentiation of acute dyspnea, rule-out-diagnostic-tests, monitoring of therapeutic responses
and prognosis of acute or decompensated CHF. The rationales as well the potential applications of NPs in these
settings are discussed in this review article.
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INTRODUCTIONHowever, with the expanding clinical uses of NPs, many
circumstances that directly or indirectly influence the heart
functions have been found to associate with elevated NPs
levels. Emerging reports have also suggested that the
determination of NPs might be helpful in screening the
presence of secondary cardiac dysfunction, monitoring the
therapeutic responses, and providing prognostic values in
many settings. Thus clinicians need to have expanded
knowledge regarding the interpretation of elevated NPs
levels and potential clinical applications of NPs.
In this review, we focus our discussion in current inves-
tigations on the interpretation and uses of elevated NPs
levels in various non-CHF settings. The rationales as well
the potential applications of NPs in these clinical settings
are discussed.
Since 1956, Kisch found secretory granules in the guinea
pig atrium; the heart is recognized not only as the pump of
the circulatory system but also an endocrine organ.
3,4 The
secretory granule was determined to be atrial natriuretic
peptide (ANP). Brain natriuretic peptide was identified from
the porcine brain tissue initially and was found primarily
synthesized from the ventricle. The name was subsequently
changed to B-type natriuretic peptide (BNP). C-type nat-
riuretic peptide (CNP) is produced by vascular endothelial
cells and the kidney and is structurally similar to ANP and
BNP. 
BNP can be produced in both atria and ventricles, and is
upregulated in failing ventricular myocardium. In response
to increased myocardial stretch and wall stress, ventricular
myocytes secret the pro-hormone pre-proBNP, which is
then cleaved into biologically active BNP and the inactive
byproduct N-terminal-proBNP (NT-proBNP). The biolo-
gical actions of NPs are mediated through membrane-
bound natriuretic peptide receptors (NPR) that are linked
to a cyclic guanosine monophosphate-dependent signaling
cascade, including NPR-A, which preferentially binds
ANP and BNP, and NPR-B, which preferentially binds
CNP. Elevated BNP levels have been demonstrated to res-
ponsed to increased angiotensin II and sympathetic tones.
5
Elevated NPs levels can be also found in many circum-
stances involving LV dysfunction or hypertrophy; right
ventricular (RV) dysfunction secondary to pulmonary
diseases; cardiac inflammatory or infectious diseases; and
endocrinology diseases and high output status without
decreased left ventricular ejection fraction (EF), e.g., sepsis,
renal failure, cirrhosis of liver, or intracranial pathologies.
Even in the absence of significant clinical evidence of
volume overload or LV dysfunction, markedly elevated
NP levels can be found in patients with multiple comorbi-
dities with certain degree of prognostic value.
6 The causes
and mechanisms of elevated NPs levels are summarized in
Fig. 1. The potential clinical applications in the non-HF
settings are summarized in Table 1. 
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PATHOPHYSIOLOGICAL
CONSIDERATIONS OF NPs
Fig. 1. The causes and mechanisms of elevated natriuretic peptides levels. *The main reason of elevated natriuretic peptides and the best-
established use of these testing. Circumstances in the example list may share more than one mechanism. 
Cardiac amyloidosis
Infective endocarditis
Myocarditis
Pericarditis
Kawasaki disease
Cardiac inhiltrative, inflammation or 
infectious diseases
Hyperthyroidism
Sepsis
Shock
Intracranial pathologies
Neurohormonal of cytokine 
cardiac stimulation
Hyperdynamic
circulation
Volume expansion
Sepsis
Critical illness
Intracranial
pathologies
Renal failure
Cirrhosis of liver
High-output status
Acute or chronic renal failure
Advanced age
Decreased clearance
Acute or decompensate heart failure*
Acute coronary syndrome
Valvular heart diseases
Cardiac dysrhythmia
Congenital heart diseases
Carbone monoxide poisoning
Systolic or diastolic left ventricular
dysfunction or hypertrophy
Pulmonary embolism
Pulmonary hypertension
Chronic lung diseases
Right ventricular dysfunction
secondary to pulmonary diseasesNPs induce vasodilatation, increase diuresis, and inhibit
renin and aldosterone production. The function of CNP
seems to be the regulation of  regional blood flow. The net
effects are decreasing cardiac preload and afterload. BNP
is eliminated by binding to the NPR-C or degradation by
neutral endopeptidase on endothelial cells, smooth muscle
cells, cardiac myocytes, renal epithelium, and fibroblasts.
NT-proBNP is cleared mainly by the kidney.
7 BNP has a
relatively shorter half-life of about 20 minutes; the half-life
of NT-proBNP is about 60-90 minutes and would be
expected to be longer in the setting of renal dysfunction.
Obese patients (especially those who have body mass
index greater than 30) tend to have lower BNP levels than
others. Neural endopeptidases that can be secreted by
adipose tissue may be related to increased BNP clearance
in obese patients.
8
During the past few years, several fully automated, rapid
assays for the determinations of BNP and NT-proBNP
have become commercially available, including both high-
throughput automated plateforms and point-of care tests.
Most immunoassays currently used in the clinical setting,
however, do not determine precise molecular forms of these
NPs, such as different cleavage points and post-translatio-
nal modifications, which may vary depending on the
pathophysiological state of CHF. In a recent study using
quantitative mass spectral methodology, the authors report-
ed the absence of circulating 32-amino acid BNP in ad-
vanced heart failure, suggesting the existence of altered
forms of BNP that contribute to the high levels measured
by conventional point-of-care tests.
9 Plastic tubes containing
ethylenedinitrolotetraacetic acid (EDTA) are desirable for
BNP determination and refrigeration is required if the
interval between blood collection and analysis is over 4
hours; whereas NT-proBNP can be measured in both serum
or plasma, collected in glass or plastic tubes, and has no
significant loss of immunoreactivity after 48 hours at room
temperature. Although these existing BNP assays correlate
closely, BNP assays are not currently analytical equivalent
due to lack of assay standardization.
10 A multicenter colla-
borative proficiency testing study conducted in 90 Italian
laboratories had demonstrates that there are significant
differences in analytical characteristics and measured values
among the most popular commercial methods for BNP and
NT-proBNP. Thus, clinicians should be very careful when
comparing results obtained by laboratories that use different
methods.
11
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Table 1.Potential Clinical Applications of Natriuretic Peptides in Selected Diseases
Diseases severity /  
Diseases Screening* risk stratification / Prognosis
monitoring of  therapy
Heart failure
� +++
Acute coronary syndrome + + +
Cardiac procedures + + +
Pulmonary embolism + + +
Pulmonary hypertension + + +
Chronic lung diseases + + -
Valvular heart diseases + + +
Cardiac dysrhythmia + + N / A
Cardiac inflammatory or infectious diseases + + + / -
Cardiogenic syncope + N / A N / A
Sleep apnea  + + N / A
Hypertension  + + N / A
Sepsis + + +
Renal failure + + +
Cirrhosis of liver + + +
Hyperthyroidism + + N / A
Intracranial pathologies + + +
Epilepsy / Seizures + - -
Carbone monoxide poisoning  + N / A N / A
N/A, not available.
*Screening for the presence of cardiac dysfunction.
�The best-established clinical application of these natriuretic peptides testing.Shih-Hung Tsai, et al.
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Increased BNP levels correlate grossly with the severity
of left ventricular (LV) dysfunction, both clinically and
hemodynamically. It has been suggested that NT-proBNP
levels also correlate and provide important prognostic
information beyond echocardiographic parameters of car-
diac structure and function.
12 In 72 patients with various
degrees of LV systolic dysfunction, a head-to-head com-
parison for performance of BNP and NT-proBNP to detect
LV systolic dysfunction was performed. Similar to BNP,
NT-proBNP is a promising marker in identifying LV
systolic dysfunction. Although both assays are reliable and
have good analytical performance, their diagnostic cut-off
value is dynamic and population-dependent. The slightly
wider detection range and the more stable structure of NT-
proBNP compared to the BNP assay suggest that NT-
proBNP could play an additional role in the evaluation of
patients with LV systolic dysfunction.
13
Acute coronary syndrome (ACS)
In a prospective observational study of 100 patients pre-
senting with chest pain, Brown, et al. had reported that
mean BNP levels in patients with cardiac chest pain was
significantly greater than that for patients with non-cardiac
chest pain. Comparing to cardiac troponin (cTn) T, BNP
was less specific for myocardial injury, but more sensitive
for the detection of acute cardiac chest pain. Combining
BNP and cTn T significantly increased the sensitivity from
55.6% to 95.6% in detecting cardiac chest pain and was
also a satisfactory rule out test (negative predictive value,
NPV of 96%) for excluding chest pain that had a cardiac
origin.
14 Anemia (Hb < 12 g/dL for females; < 13 g/dL for
males) was also associated with elevated NPs levels in
patients with known or suspected coronary artery disease.
15
NT-proBNP is also a sensitive marker of myocardial ische-
mia that rises much higher in the earlier phase compared
with conventional markers of myocardial damage, especi-
ally in non-ST elevation -MI patients.
16
In patients with ACS, BNP is a powerful indicator of
acute HF.
17 In a prospective study involving 74 patients
with ST elevation MI, increased BNP levels are associated
with progressive ventricular dilatation and development of
clinical heart failure and powerful markers of LV systolic
dysfunction as well poor prognosis after MI.
18 In a study
following 276 patients presented to the emergency depart-
ment with chest pain for 90 days, baseline elevated BNP
and NT-proBNP levels were predictive of adverse events,
i.e., ED re-visiting for chest pain, cardiac readmission, and
death at 30 and 90 days.
19 Besides, BNP levels were signi-
ficantly higher in patients with multivessels than those
with only single-vessel diseases.
20 Multivariate logistic reg-
ression analysis incorporating age, gender, history of
hypertension, diabetes, LVEF, cTn I, and therapeutic
regimens indicated that BNP was an independent predictor
of cardiac death in ACS patients.
21 In an outpatient follow-
up study, ACS patients who had newly elevated BNP
levels at 4 months were at increased risk of death or newly
developed HF. Patients with elevated BNP levels at study
entry and with BNP levels lower than 80 pg/mL at 4 months
tended to have only modestly increased risk compared to
patients with BNP levels lower than 80 pg/mL at both
visits. Patients with BNP levels of more than 840 pg/mL
and increased cTn levels are at a particularly high risk for
mortality.
22 In addition to Thrombolysis In Myocardial
Infarction (TIMI) risk score, multi-marker risk approach
based on cTnT, C-reactive protein (CRP), and NT-proBNP
was associated with adverse events at 6 months.
23 Changes
in BNP levels over time were associated with long-term
clinical outcomes.
24 
Percutaneous cardiac intervention, cardiac surgery, 
heart transplantation, and the use of extracorporeal 
membrane oxygenation 
BNP levels obtained at post-PCI 24th hour were inde-
pendent predictors of major adverse cardiac events (MACE),
including cardiac death, MI, hospitalization with angina or
repeat revascularization during 12 months of follow-up
after elective successful PCI.
25 In 26 patients that received
the implantation of a paclitaxel-eluting stent, symptomatic
re-stenosis after implantation of a paclitaxel-eluting stent
could be predicted by the combination of a basal plasma
BNP level of more than 50 pg/mL and a positive or incon-
clusive conventional exercise test. Thus, determining basal
BNP levels could improve both the detection and exclu-
sion of asymptomatic re-stenosis.
26 In 135 patients under-
going various cardiac procedures, serum NT-proBNP is a
good predictor for complications after cardiac surgery, is
as good as the European system for cardiac operative risk
evaluation, and better than EF alone.
27 In 85 patients under-
going first-time elective CABG, preoperative BNP levels
could be used to predict the development of postoperative
new-onset atrial fibrillation (AFib), a need for inotropic
support, and a requirement for intra-aortic balloon pump.
28
In 149 that patients underwent cardiac surgery, BNP levels
measured at the beginning of the rehabilitation program
had been found to be independent predictors of late AFib
after cardiac surgery.
29
Despite the absence of a ventricular stretch or intracar-
diac pressure derangement, elevated BNP levels were
found after cardiac transplantation; thus it had been impli-
cated as a marker for allograft rejection, adverse prognosis,
and coronary graft vasculopathy in these patients.
30 BNP
CARDIAC DISEASESlevels have high sensitivity and NPV for acute rejection in
pediatric heart transplant patients. In 86 that patients
underwent a total of 560 endomyocardial biopsies in
patients > 1 year post-transplant, a BNP level of < 100
pg/mL correlated with a < 1% chance of aortic regurgitation
(AR) and may obviate the need for biopsies in some
cases.
31 In an observational study that included 71 heart
transplant patients, the increase between the two serial
determinations of BNP levels at the end of the first year
post-transplant indicated a subgroup of patients with a
poorer outcome.
32
In 19 children supported with a pulsatile ventricular
assist device, extremely high levels of NPs reflect the sev-
erity of myocardial failure before extracorporeal membrane
oxygenation implantation. During mechanical support, the
decline of NPs appears to be an additional tool in the pre-
selection of potential weaning candidates.
33
RV dysfunction secondary to pulmonary diseases 
Pulmonary embolism
NPs levels are elevated in most patients with acute PE
complicated with RV overload or dysfunction.
34 In 93
consecutive outpatients diagnosed with acute PE by means
of helical computed tomography (CT), plasma levels of
NT-proBNP greater than 500 ng/L were independently
associated with central PE (in the main trunk or right or
left main branches of the pulmonary artery) and perhaps as
a predictor of death.
35 The presence of RV dysfunction
should be strongly considered in patients with plasma BNP
levels of more than 90 pg/mL.
36 BNP levels significantly
associated with the severity of pulmonary hypertension and
increased ventilation-perfusion mismatch on scintigraphy
also corresponded to incremental increases in the levels of
ANP and BNP. The combination of NT-proBNP or cTn
tests to echocardiography could aid risk stratification in
patients with acute PE.
37 
An aggressive therapy such as thrombolytic therapy may
be beneficial in patients with acute massive or non-mas-
sive PE with RV dysfunction. Thrombolysis significantly
reduced systolic pulmonary pressure, and declined BNP
and cTn I levels were indicators of the efficacy of pharma-
cological treatment in patients with acute PE.
38 After
pulmonary thromboendarterectomy, plasma BNP levels
markedly decreased in association with a reduction of total
pulmonary resistance in survivors. The changes of plasma
BNP levels were closely correlated with the total pulmo-
nary resistance. Sustained elevated plasma BNP levels
indicated the presence of residual pulmonary hypertension
after operation. In hemodynamically stable PE, BNP/cTnI
measurement could be helpful on admission, especially for
ruling out circulatory failure and in-hospital death.
39
Pulmonary hypertension
In patients with RV pressure overload due to primary
pulmonary hypertension (PPH) and thromboembolism,
plasma BNP levels correlated with mean pulmonary artery
pressure, right atrial pressure, RV end-diastolic pressure,
and total pulmonary resistance.
40 In 49 dyspneic patients
(25 with chronic obstructive pulmonary disease (COPD), 8
with interstitial pneumonia, 16 with sequelae of tuberculo-
sis), hypoxemia was more severe in patients with higher
BNP levels than those with lower BNP levels.
41 In a study
involving 61 patients with various forms of chronic pulmo-
nary hypertension, plasma NT-proBNP levels can be used
to determine the clinical severity and are independently
associated with long-term mortality.
42 
Chronic lung diseases and respiratory failure
Elevated BNP levels have been found in hypoxemic pa-
tients with COPD, particularly in patients with cor pulmo-
nale when compared with patients with COPD alone. BNP
levels increased in proportion to the severity of RV dysfunc-
tion and could be a useful indicator of RV dysfunction.
43
Adding mild diuretics to the standard treatment for an
acute exacerbation (AE) of COPD may rapidly reduce
plasma BNP levels in COPD patients with AE who have
elevated BNP levels without any clinical evidence of cor
pulmonale.
44 In 208 patients presenting to the ED with an
AE of COPD, BNP levels were significantly elevated
during AE compared to recovery. In these patients, BNP
levels independently predict the need for intensive care
unit (ICU). However, BNP levels failed to predict short-
and long-term mortality in these patients.
45 
Cardiovascular dysfunction is responsible for a majority
of weaning failure. In 52 patients recovering from acute
respiratory failure, the extubation failure group had signi-
ficantly greater increases in BNP levels at the end of
spontaneous breathing trial (SBT) than the extubation
success groups. Thus, measuring the percentage change in
the BNP levels during a SBT may help to improve the
predictive value of SBT on weaning outcomes.
46
Valvular heart disease
Mitral valve
Natriuretic peptides levels increase with increasing severity
of mitral regurgitation (MR) and had been shown to be a
marker of poor outcome in patients with organic MR.
47
NT-proBNP levels were significantly greater in patients
with severe mitral stenosis (MS) than in moderate MS.
NT-proBNP levels were also significantly higher in patients
with mitral valve replacement than in controls. There were
positive correlations between BNP level with the degree of
MS, pulmonary artery pressure, and a negative correlation
Natriuretic Peptides in Non-CHF Settings
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48 Serum NT-proBNP levels cor-
related well with echocardiographic findings and functio-
nal class in patients with MS.
49
Aortic valve
In Patients < 70 years old with mild to moderate aortic
stenosis (AS) with a peak transaortic gradient > 20 mm Hg,
NT-proBNP levels increased even in asymptomatic
patients with AS and correlated with echocardiographic
parameters related to the severity of AS and degree of
diastolic dysfunction.
50 Preoperative NT-proBNP correlated
significantly with diastolic and systolic LV wall stress
assessed by echocardiography. Independent to preopera-
tive LV mass index, higher pre-operative levels of NT-
proBNP predicted a greater magnitude of total LV mass
regression at follow-up.
51
NPs could be used as an additional noninvasive method
in monitoring disease progression and have potential prog-
nostic usefulness in adjunct to echocardiography. In high-
risk patients, BNP has been also considered to be useful
for monitoring the progression of VHD.
52 Detection of a
cardiac murmur during routine medical examinations of
hospitalized patients is associated with increased risk of
death within a year. Determining NT-proBNP gives signi-
ficant additional prognostic information of a murmur and
could obviate the need for echocardiography in selected
patients with a murmur and normal NT-proBNP for whom
surgery is not feasible.
53
Cardiac dysrhythmia
In 60 patients with persistent AFib evaluated before
cardioversion and 1, 30 and 180 days after cardioversion, a
medium-low elevation of NT-proBNP indicated only an
acute response to the distension of the atrial tissue induced
by the arrhythmia; in contrast, markedly elevated values
might be caused by ventricular dysfunction or hypertro-
phy. AFib may cause enduringly elevated ANP and BNP
level. Changes in left atria (LA) volume correlated well
with the changes in ANP and BNP levels following car-
dioversion; and atrial volume seems to be an important
determinant of ANP and BNP in AFib.
54 In 43 patients
undergoing persistent/permanent AFib ablation, sinus
rhythm (SR) following persistent/permanent AFib ablation
is associated with a dramatic decrease in NPs with signi-
ficantly improved cardiac functions, even after relatively
extensive atrial ablation.
55 Plasma NT-proBNP levels
obtained before electrical cardioversion did neither predict
cardioversion success nor relapse of AFib in patients
without HF. However, maintained SR during follow-up
was associated with a significant reduction in NT-proBNP
levels.
56 Significant reduction in BNP levels after pul-
monary vein isolation was associated with therapeutic
responses to antiarrhythmic drug therapy in patients with
recurrent AFib after the procedure.
57 In a study including
20 open-heart surgery patients with concomitant AFib,
NPs levels tended to decrease in patients with stable SR at
one year compared to patients in AFib.
58 In 105 patients
presented to the ED with a recent-onset AFib and supra-
ventricular tachycardia, SR was restored in a low per-
centage of patients with NT-proBNP of greater than 4,500
pg/mL, while the vast majority of those with values < 1,500
pg/mL was normalized even by means of antiarrhythmic
drugs alone. The evaluation of NT-proBNP could be used
as an alternative to echocardiography to rapidly select
patients in whom cardioversion should be attempted in the
ED.
59
High degree atrioventricular block can induce elevated
plasma BNP levels and the atrioventricular dyssynchrony
further induce elevated BNP levels. In 34 patients with
preserved LV systolic function on permanent RV apical
pacing, RV apical pacing is associated with LV dyssyn-
chrony and subsequent accelerated BNP secretion.
60 In a
study involving 43 children and adolescents with high-
grade second degree or complete atrioventricular conduc-
tion block, plasma BNP levels were significantly higher in
patients without pacemaker than in those with permanent
pacemaker. Additionally, patients with dual-chamber pac-
ing had significantly lower BNP values compared to those
with single chamber ventricular pacing.
61
Miscellaneous uses in cardiac diseases
Cardiac inflammatory and infectious diseases  
Increased release of BNP into the circulation may be a
general feature of cardiac inflammation or injury. Inflam-
matory process can contribute specific cytokines leading to
the disregulation of cardiac ANP and BNP production ob-
served during myocardial inflammation and this process
might be angiotensin receptor 1-dependent.
62 In 14 patients
with suspected acute perimyocarditis, BNP level are incre-
ased in some patients with acute perimyocarditis. BNP
elevation is probably associated with hemodynamical
stress caused by transient contractility abnormalities.
63 In
45 patients with confirmed infective endocarditis, admission
NT-proBNP levels of more than 1,500 pg/mL had signifi-
cantly lower event-free survival than others. The combina-
tion of admission NT-proBNP and cTnI levels appeared to
have even greater value for risk stratification in these
patients.
64 In a prospective study involving 45 patients with
acute and convalescent rheumatic fever, BNP levels were
higher compared to those of healthy subjects and could be
used as a complementary tool in the treatment and pro-
gnosis of acute rheumatic fever.
65 In 13 pediatric patients
with Kawasaki disease, NT-proBNP levels increased in the
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phase.
66
Restrictive cardiomyopathy and constrictive pericarditis
Restrictive cardiomyopathy (RCM) and constrictive peri-
carditis (CP) are difficult to distinguish clinically and pose
a diagnostic challenge. In 11 patients suspected of having
either CP or RCM suffered New York Heart Association
(NYHA) stage III-IV CHF with similar elevation in intra-
cardiac pressures, BNP levels were markedly elevated in 5
patients with RCM than 6 patients with CP.
67 In addition,
patients with idiopathic CP had significantly lower levels
of BNP than those with RCM and those with CP secon-
dary to radiation and cardiac surgery.
68
Cardiogenic syncope
In 61 patients admitted to a university hospital due to syn-
cope, NT-proBNP at a cut-off of 164 pg/mL identified
patients with cardiac syncope and patients requiring inter-
ventional therapy with high sensitivity and NPV. Assess-
ment of NT-proBNP might be helpful in differentiating
cardiac from non-cardiac syncope and could effectively
reduce the use of Holter echocardiography, telemetry mon-
itoring, stress tests, echocardiography, coronary angio-
graphies, and electrophysiological examinations in synco-
pal patients.
69 
Sleep apnea and morbid obesity
Cardiac structural and functional abnormalities were ob-
served with increased severity of sleep apnea. In 235
patients evaluated in a sleep clinic for obstructive sleep
apnea, elevated BNP levels seemed to reflect an increased
likelihood of LV hypertrophy in patients with severe sleep
apnea.
70 In a cross-sectional study involving 110 morbid
obesity, healthy young female patients, NT-proBNP levels
were independently predicted by sleep-disordered breath-
ing and insulin resistance.
71
Hypertension
In 154 untreated hypertensive patients without heart failure
or AFib, logarithmic BNP was positively correlated with
age, pulse pressure, cardiac hypertrophy, and diastolic dys-
function, and negatively correlated with hemoglobin, renin
levels, and E/A ratio. Thus BNP might be useful in initial
assessment of the severity of essential hypertension and
may be also valuable for risk stratification.
72
Aortic dissection 
Both acute aortic dissection (AAD) and chronic aneury-
sms of the ascending aorta were associated with long-
standing hypertension, which is often accompanied by LV
diastolic dysfunction and AR. In 18 patients with AAD,
both patients with AAD and chronic uncomplicated
aneurysms had significant higher BNP levels than normal
controls.
73
Congenital heart diseases 
Although clinical and echocardiographic signs define hemo-
dynamic significance of patent ductus arteriosus (PDA),
they are not predictive of the need for PDA intervention in
the first days of life. In a prospective blinded study involving
67 preterm infants on the second day of life, plasma BNP
levels positively correlated with ductal size and LA/Aorta-
ratio significantly.
74 Plasma NT-proBNP levels on day 3
are a good marker for hemodynamic significant PDA in
preterm infants. Serial measurements of NT-proBNP may
be useful in assessing the clinical course of PDA.
75
Cardiac amyloidosis 
In a study evaluating heart involvement in 152 patients
with amyloidosis, NT-proBNP is a sensitive marker of
cardiac dysfunction and a strong predictor of outcome in
cardiac amyloidosis and had been shown to decline with
treatment.
76
Infectious diseases and sepsis
Ventricular dysfunction with reduced EF and biventricular
dilatation is present in most patients with severe sepsis and
septic shock. Plasma ANP, NT-proBNP, and BNP were
significantly elevated in septic shock patients than healthy
control subjects. In a study involving 54 patients without
heart diseases, BNP levels could be elevated in the acute
phase of community-acquired microbial infections, parti-
cularly in patients with diabetes mellitus (DM) and lower
respiratory tract infection, even in the absence of severe
sepsis or septic shock.
77 In a study involving 50 patients
with septic shock, elevated BNP levels were significantly
associated with myocardial dysfunction and severity of
global tissue hypoxia. BNP levels were positively correlated
with CRP levels in septic patients without clinical or echo-
cardiographic evidence of volume overload or systolic
dysfunction.
78 In patients with community-acquired pneu-
monia (CAP), BNP level was an independent predictor of
treatment failure and death. In a study evaluating 302
consecutive patients presenting to the ED with CAP, when
used in conjunction with the pneumonia severity index
(PSI), BNP levels significantly improved the risk prediction
when compared with the PSI alone.
79 Patients with septic
Natriuretic Peptides in Non-CHF Settings
Yonsei Med J   http://www.eymj.org    Volume 51   Number 2   March 2010 157
CAUSES OF ELEVATED NPs LEVELS DUE
TO HYPERDYNAMIC STATUS, OTHER
SECONDARY CARDIAC DYSFUNCTIONS,
OR DECREASED CLEARANCEshock had significantly higher BNP levels on admission
compared to patients with early sepsis and healthy subjects.
BNP levels for patients with septic shock were positively
correlated with Sequential Organ Failure Assessment
scores and prognosticated survival.
80 NT-proBNP is an
independent prognostic marker of mortality in severe sepsis
and both NT-proBNP obtained on admission and 72-hours
after admission are significantly higher in nonsurvivors
than survivors.
81 
Renal failure
In a study involving 164 hemodialysis patients, elevated
BNP levels were associated with volume overload, LV
hypertrophy, cardiovascular disease and DM, and may be
a useful parameter for assessing the risk of cardiac death in
these patients.
82 Renal function clearly influences the
diagnostic performance of NT-proBNP; Goei, et al. had
showed that NT-proBNP had more favorable discrimina-
tive value in patients with glomerular filtration rate (GFR)
more than 90 mL/min/1.73 m
2 and lost its prognostic value
in patients with GFR less than 30 mL/min/1.73 m
2.
83 Unlike
NT-proBNP, BNP levels are relatively independent of
GFR. BNP may therefore be the more appropriate bio-
marker to screen for cardiac dysfunction in patients with
renal failure.
84 BNP levels could be a valuable tool for risk
stratification of hemodialysis patients by confining echo-
cardiographic studies to only patients with BNP levels
above the established cutoff values.
85
On the basis of the German Diabetes and Dialysis Study
which evaluated atorvastatin in 1255 type 2 DM hemo-
dialysis patients with a median follow-up of 4 years,
patients with baseline NT-proBNP of more than 9,252
pg/mL exhibited a more than four-fold risk of stroke and a
more than two-fold risk of sudden death, cardiovascular
events, and mortality compared with patients with baseline
NT-proBNP less than 1,433 pg/mL. Doubling of NT-
proBNP increased the risk of death by 46%.
86
Cirrhosis of liver
In patients with cirrhosis of the liver, elevated proBNP and
BNP levels reflect increased cardiac ventricular generation
of NPs and thus indicates the presence of cardiac dys-
function. Hyperdynamic systemic circulation could also be
contributed to elevated NPs levels in patients with cirrhosis
of liver. In a study evaluating 52 non-alcoholic cirrhotic
patients, BNP levels were significantly higher in cirrhotic
patients complicated with ascites, spontaneous bacterial
peritonitis and hepatic encephalopathy history, but no
significant differences were observed for the presence of
esophageal varices and bleeding history. BNP levels signi-
ficantly correlated with Child score, interventricular septal
thickness, and LV posterior wall thickness.
87 In 51 cirrhotic
patients during a hemodynamic investigation, circulating
proBNP and BNP levels were related to the severity of
liver decompensation (Child score, serum albumin, coa-
gulation factors, and hepatic venous pressure gradient) and
to markers of cardiac dysfunction (QT interval, heart rate,
plasma volume).
88
Critical illness and shock 
Assessing cardiac filling pressure and cardiac performance
are important in patients with either noncardiogenic or
cardiogenic shock. Low NT-proBNP values may be useful
in excluding the need for pulmonary artery catheter place-
ment in patients with ICU shock and identified those at
lower risk for death.
89 In a prospective, blinded cohort
study that incorporated 54 patients admitted to the ICUs
with respiratory distress, bilateral pulmonary edema and a
central venous catheter suggesting either high-pressure
(cardiogenic) or low-pressure, acute lung injury acute
respiratory distress syndrome (ALI/ARDS) pulmonary
edema, BNP at an accepted cutoff of 100 pg/mL had a high
specificity for the diagnosis of ALI/ARDS (95.2%), but
the sensitivity was poor (27.3%). BNP levels drawn within
48 hours of admission to the ICU did not correlate with
invasive hemodynamic measurements and did not track
predictably with changes in volume status on consecutive
daily measurements.
90 Patients with significant blood loss
(decreased hemoglobin level more than 3 g/dL) had signi-
ficant lower BNP levels than those without blood loss.
Thus, BNP levels below normal are indicative of intravas-
cular volume loss in traumatically injured patients.
91 In a
study evaluating 40 patients who had pre- and post transfu-
sion NT-proBNP determinations, NT-proBNP could also
be used to evaluate the development of transfusion asso-
ciated circulatory overload with a sensitivity of 93.8% and
specificity of 83.8%. Elevated post transfusion NT-proBNP
is the only independent variable for this diagnosis.
92 NT-
proBNP on admission is an independent prognostic marker
of outcome in an unselected cohort of critically ill patients.
Measurement of NT-proBNP might facilitate triage of
critical ED and ICU patients.
93 
Hyperthyroidism
Serum NT-proBNP levels are affected by thyroid functions
and seem to be a direct stimulatory effect of thyroid hor-
mones.
94 A comparison between 67 patients with clinical
hyperthyroidism and normal subjects, elevated BNP levels
were mainly found in hyperthyroid patients who had
clinical and echocardiographic evidence of LV dysfunction
(increased LA diameter and decreased LVEF) but not in
those with normal LV function and normal subjects.
95
Multiple linear regression analysis demonstrated that free
T4 and free T3 were independently associated with a high
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pulse rate were not. In 21 patients with hyperthyroidism,
both NT-proBNP and BNP levels were higher than hypo-
thyroid patients and normal controls; and treatment of
thyroid dysfunctions could result in normalization of NT-
proBNP levels in both hypothyroid and hyperthyroid
groups.
96
Intracranial pathologies 
Acute ischemic stroke 
A stress response consisting of elevated levels of cortisol
and catecholamines is common after acute ischemic stroke
(AIS). Activation of the hypothalamus-pituitary-adrenal
axis in patients with AIS is associated with elevated levels
of NPs.
97 NT-proBNP levels were elevated in patients with
AIS. In a study involving 30 patients with an AIS, the
activated neurohumoral responses occurring in patients
with AIS reflect either a counterbalancing vasodilating
response to the cerebral ischemia or direct myocardial
dysfunction.
98 The log NT-proBNP correlated positively
with cTnI and heart rate, and negatively with LVEF; and
patients with signs of marked myocardial ischemia or
insular cortex involvement had particularly higher NT-
proBNP levels. BNP levels in AIS patients without AFib
were correlated with MAP on admission or the degree of
reduction in MAP at day 1. While in AIS patients with
AFib, BNP levels showed a negative correlation with
MAP on admission.
99 Even in patients without AFib, the
presence of at least one LA or appendage abnormality
(atrial dilatation, low flow velocity, spontaneous echocon-
trast, or thrombus) had the strongest association with an
elevated BNP, suggesting that BNP level could be a poten-
tial marker for the presence of LA sources of emboli.
100 In a
study involving 707 patients presenting to the ED with
AIS, BNP of more than 76 pg/mL was an independent pre-
dictor of cardioembolic stroke. Even among patients with
transient symptoms, a high BNP level identified cardioem-
bolic etiology.
101 Elevated NPs and cortisol levels predict
long-term mortality after AIS, suggesting that this profound
neurohumoral disturbance is prognostically unfavorable.
102
Subarachnoid hemorrhage
Cardiovascular abnormalities are independent predictors of
in-patient mortality after a subarachnoid hemorrhage (SAH).
Patients with SAH showed an increased urine output and
urinary excretion of sodium as well as higher BNP levels
than the controls.
103,104 In a study involving 50 patients with
traumatic SAH, early after SAH, elevated BNP levels are
associated with myocardial necrosis, pulmonary edema,
and LV dysfunction. BNP levels may be elevated in patients
with head injuries without echocardiographic evidence of
HF.
105 In the absence of evidence for activation of NPs
within the brain, prompt and consistent increase in both
ANP and BNP strongly supports the view that the heart is
the source of increased NPs release after acute SAH.
106 In a
study involving 30 patients with severe isolated head in-
jury, BNP levels are elevated shortly after head injury and
progressively elevated through days 7-8 after the event in
patients with diffused SAH as compared to patients with
mild or no SAH; and in patients with elevated intracranial
pressure (ICP) as compared to patients without elevated
ICP as well as a poorer outcome.
107 In a study involving 14
patients suffering from severe traumatic brain injury, NT-
proBNP levels in cerebral spinal fluid and serum were
significantly elevated in patients exhibiting an ICP of more
than 15 mmHg.
108 In a prospective cohort study incorpo-
rating 300 patients with aneurysmal SAH, an initial BNP
level greater than 600 pg/mL was markedly associated
with death.
109
Epilepsy 
In a study incorporating 65 postictal children and 31 chil-
dren with epilepsy after a seizure-free period for at least 2
months serving as controls, NT-proBNP levels were signi-
ficantly higher 4 hours after a seizure attack compared to
24-48 hours after a seizure attack. Serum NT-proBNP
levels were higher in children with tonic-clonic seizures
and febrile convulsions than those with partial motor
seizures, syncope, or normal subjects.
110 Obi, et al. had
reported a patient who had episodic elevation of ANP and
BNP during epileptic activity caused by a left frontotem-
poral lesion. ANP and BNP were assumed to release from
the heart by the epileptic stimulation on the anterior ventral
region of the third ventricle.
111
Carbon monoxide poisoning
The level of NT-proBNP and carbon monoxide (CO) Hb
were increased in patients with CO poisoning. In a study
involving 15 patient with CO poisoning, there was a posi-
tive correlation between the levels of COHb and NT-
proBNP. Thus, determining plasma NT-proBNP levels
may contribute to the early diagnosis of cardiotoxicity in
patients with CO poisoning.
112
Elevated NPs levels have shown predictive value in various
diseases that have direct or indirect influences on the heart
functions in many non-HF circumstances, even in the
absence of depressed cardiac function. It should be noted
that NPs should never be interpreted without thorough
clinical messages. NPs are very sensitive for primary or
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secondary cardiac dysfunction, but the specificity is low.
Potential clinical applications of NPs are expanded, accom-
panied by emerging reports regarding to screening for the
presence of secondary cardiac dysfunction, monitoring the
therapeutic responses, risk stratifications, or providing
prognostic values in many settings. Clinical decision on
timely and costly cardiac examinations or more risky and
invasive procedures rather than deferred, conservative
strategies might be facilitated by appropriate use and inter-
pretation of NPs. However, clinicians should recognize
that currently the only reasonable application for routine
practice is limited to differentiation of acute dyspnea, rule-
out-diagnostic-tests (high NPV and low positive predictive
values), monitoring of therapeutic responses, and prognosis
of acute or decompensated CHF.
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